Β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome by H. Bas de Laat, Ronald H.W.M. Derksen,

Slides:

Advertisements

Similar presentations

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.

Advertisements

Anti-Phospholipid Antibody Syndrome The Annexin A5 Competition Assay as a Diagnostic Tool.

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,

General Approach of Haemostasis

MIXING STUDIES General Approach of Haemostasis

Correlation and Prediction Error The amount of prediction error is associated with the strength of the correlation between X and Y.

Anti-Phospholipid Syndrome (APS)

Normal Distribution.

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca ++ -dependent complex of C-reactive protein with very-low–density.

Date of download: 9/18/2016 From: Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants Ann Intern Med. 1997;127(3): doi: /

One-Stage Quantitative

Antiphospholipid Antibody Syndrome

General Approach of Haemostasis

General Approach in Investigation of Hemostasis

Mixing Studies-aPTT or PT 1:1 Mix

The influence of high-altitude living on body iron

Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke by Valérie Wolff, Boris Aleil, Maurice Giroud, Jean-Louis Lorenzini,

Discounted Coagulation Profiles Clinical Laboratories.

Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts by Esther R. van Bladel,

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

MBL: mostly benign lymphocytes, but…

Activation of αIIbβ3 is a sufficient but also an imperative prerequisite for activation of α2β1 on platelets by Gerlinde R. Van de Walle, Anne Schoolmeester,

Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.

by Khaled M. Musallam, Vijay G

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma by Jean-Louis H. Kerkhoffs,

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.

Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants by Rachael P. Jackman, Xutao Deng, Douglas Bolgiano, Mila.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

Β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome by Kenji Tanimura, Hui Jin, Tadahiro Suenaga, Satoko Morikami,

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing by Michael Dechant, Gestur Vidarsson, Bernhard Stockmeyer, Roland.

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with.

Genetic sequence analysis of inherited bleeding diseases

by Laurent O. Mosnier, Andrew J

Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk by Alisa S. Wolberg, Dougald.

Potential Role for Hyaluronan and the Hyaluronan Receptor RHAMM in Mobilization and Trafficking of Hematopoietic Progenitor Cells by Linda M. Pilarski,

by Monica Galli, Luisa Ruggeri, and Tiziano Barbui

by Gerald de Haan, Willem Nijhof, and Gary Van Zant

by James D. Cook, Carol H. Flowers, and Barry S. Skikne

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Robert McMillan, Jennifer Lopez-Dee, and Joseph C. Loftus

Stage C or not stage C…? by Claire Dearden Blood

by Andrew J. Gale, Mary J. Heeb, and John H. Griffin

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor by Anne F. Riddell,

Coagulation and fibrinolytic activities in 2 siblings with β2-glycoprotein I deficiency by Rie Takeuchi, Tatsuya Atsumi, Masahiro Ieko, Hiroyuki Takeya,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin by Romy M. W. Kremers, Stéphane Zuily, Hilde Kelchtermans,

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors by Manu T. Kalathottukaren, A.

Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies by Grace M. Lee, Manali Joglekar, Maragatha Kuchibhatla, Sanjay Khandelwal,

Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes by Edward N. van den Brink, Ellen A. M. Turenhout,

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma by Tineke Casneuf, Xu Steven.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Plasma biomarker concentrations between study groups.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.

Hexagonal Phospholipid Neutralization assay (STACLOT-LA).

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Association of MRI findings and serum autoantibodies in diffuse neuropsychiatric systemic lupus erythematosus. Association of MRI findings and serum autoantibodies.

How I treat heparin-induced thrombocytopenia and thrombosis

Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state by Jeremy P. Wood, Lisa M.

Patient Tregs express normal levels of suppression.

Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S by José A. Fernández, Xiao Xu, Ranjeet K.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

A change in either volume of distribution or clearance has differing effects on the concentration-time profile. A change in either volume of distribution.

Presentation transcript:

β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome by H. Bas de Laat, Ronald H.W.M. Derksen, Rolf T. Urbanus, Mark Roest, and Philip G. de Groot Blood Volume 104(12):3598-3602 December 1, 2004 ©2004 by American Society of Hematology

Addition of cardiolipin in APTT-based LAC assay. Addition of cardiolipin in APTT-based LAC assay. Plasmas of 2 patients were diluted 1:1 with normal pool plasma and incubated with different concentrations of cardiolipin and reagent (Diagnostica Stago). As a reference we performed the same assay with normal pool plasma. An LAC was characterized as β2-GPI dependent when the ratio of patient plasma divided by normal plasma decreased by at least 0.05 at 25 μM cardiolipin compared with no addition of cardiolipin. Coagulation was initiated by the addition of CaCl2, and clotting time was measured. H. Bas de Laat et al. Blood 2004;104:3598-3602 ©2004 by American Society of Hematology

The association between antibody distribution and thrombosis. The association between antibody distribution and thrombosis. Numbers are displayed as odds ratios (95% confidence intervals) and are calculated by logistic regression. H. Bas de Laat et al. Blood 2004;104:3598-3602 ©2004 by American Society of Hematology

The distribution of thrombosis in 5 assays. The distribution of thrombosis in 5 assays. Numbers are depicted as absolute numbers of patients. H. Bas de Laat et al. Blood 2004;104:3598-3602 ©2004 by American Society of Hematology